TY - JOUR
T1 - Common data elements for preclinical epilepsy research
T2 - Standards for data collection and reporting. A TASK3 report of the AES/ILAE Translational Task Force of the ILAE
AU - Harte-Hargrove, Lauren C.
AU - French, Jacqueline A.
AU - Pitkänen, Asla
AU - Galanopoulou, Aristea S.
AU - Whittemore, Vicky
AU - Scharfman, Helen E.
N1 - Funding Information:
The work by the TASK3 group is supported by the International League Against Epilepsy (ILAE), the American Epilepsy Society (AES), and the National Institute of Neurological Disorders and Stroke (NINDS).
Funding Information:
Aristea S. Galanopoulou acknowledges grant support by NINDS RO1 NS091170, U54 NS100064, the United States Department of Defense (W81XWH-13-1-0180), the Citizens United for Research in Epilepsy (CURE) Infantile Spasms Initiative, and research funding from the Heffer Family, the Segal Family Foundations and the Abbe Goldstein/Joshua Lurie and Laurie Marsh/Dan Levitz families. Helen E. Scharfman acknowledges the support of the NY State Office of Mental Health.
Publisher Copyright:
Wiley Periodicals, Inc. © 2017 International League Against Epilepsy
PY - 2017/11
Y1 - 2017/11
N2 - The major objective of preclinical translational epilepsy research is to advance laboratory findings toward clinical application by testing potential treatments in animal models of seizures and epilepsy. Recently there has been a focus on the failure of preclinical discoveries to translate reliably, or even to be reproduced in different laboratories. One potential cause is a lack of standardization in preclinical data collection. The resulting difficulties in comparing data across studies have led to high cost and missed opportunity, which in turn impede clinical trials and advances in medical care. Preclinical epilepsy research has successfully brought numerous antiseizure treatments into the clinical practice, yet the unmet clinical needs have prompted the reconsideration of research strategies to optimize epilepsy therapy development. In the field of clinical epilepsy there have been successful steps to improve such problems, such as generation of common data elements (CDEs) and case report forms (CRFs and standards of data collection and reporting) by a team of leaders in the field. Therefore, the Translational Task Force was appointed by the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES), in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institutes of Health (NIH) to define CDEs for animal epilepsy research studies and prepare guidelines for data collection and experimental procedures. If adopted, the preclinical CDEs could facilitate collaborative epilepsy research, comparisons of data across different laboratories, and promote rigor, transparency, and impact, particularly in therapy development.
AB - The major objective of preclinical translational epilepsy research is to advance laboratory findings toward clinical application by testing potential treatments in animal models of seizures and epilepsy. Recently there has been a focus on the failure of preclinical discoveries to translate reliably, or even to be reproduced in different laboratories. One potential cause is a lack of standardization in preclinical data collection. The resulting difficulties in comparing data across studies have led to high cost and missed opportunity, which in turn impede clinical trials and advances in medical care. Preclinical epilepsy research has successfully brought numerous antiseizure treatments into the clinical practice, yet the unmet clinical needs have prompted the reconsideration of research strategies to optimize epilepsy therapy development. In the field of clinical epilepsy there have been successful steps to improve such problems, such as generation of common data elements (CDEs) and case report forms (CRFs and standards of data collection and reporting) by a team of leaders in the field. Therefore, the Translational Task Force was appointed by the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES), in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institutes of Health (NIH) to define CDEs for animal epilepsy research studies and prepare guidelines for data collection and experimental procedures. If adopted, the preclinical CDEs could facilitate collaborative epilepsy research, comparisons of data across different laboratories, and promote rigor, transparency, and impact, particularly in therapy development.
KW - Common data elements
KW - Epilepsy
KW - Guidelines
KW - Preclinical
KW - Standardization
UR - http://www.scopus.com/inward/record.url?scp=85033396246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033396246&partnerID=8YFLogxK
U2 - 10.1111/epi.13906
DO - 10.1111/epi.13906
M3 - Article
C2 - 29105074
AN - SCOPUS:85033396246
SN - 0013-9580
VL - 58
SP - 78
EP - 86
JO - Epilepsia
JF - Epilepsia
ER -